| # | Title | Journal | Year | Citations |
|---|
| 1 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | New England Journal of Medicine | 2015 | 7,696 |
| 2 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade | Science | 2017 | 4,945 |
| 3 | The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions | Journal of Nutrition | 2020 | 386 |
| 4 | Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes | Gastroenterology | 2015 | 273 |
| 5 | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study | Clinical Cancer Research | 2020 | 132 |
| 6 | Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma | JAMA Oncology | 2019 | 127 |
| 7 | Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer | Cancer Discovery | 2019 | 81 |
| 8 | A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma | Annals of Oncology | 2015 | 67 |
| 9 | Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial | Future Oncology | 2020 | 62 |
| 10 | COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer | Cancer Cell | 2022 | 61 |
| 11 | BRAF and AXL oncogenes drive RIPK3 expression loss in cancer | PLoS Biology | 2018 | 56 |
| 12 | Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with KRAS‐activated tumors | Cancer | 2016 | 55 |
| 13 | Immunotherapy in surgically resectable non-small cell lung cancer | Journal of Thoracic Disease | 2018 | 53 |
| 14 | CD4 T Cell–Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair–Deficient Tumors | Cancer Discovery | 2021 | 37 |
| 15 | High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non–Small-Cell Lung Cancer | Journal of Thoracic Oncology | 2013 | 31 |
| 16 | Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer | Breast Cancer: Targets and Therapy | 2014 | 26 |
| 17 | Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis | International Journal of Cancer | 2023 | 24 |
| 18 | Exploring the Point-of-Sale Among Vape Shops Across the United States: Audits Integrating a Mystery Shopper Approach | Nicotine and Tobacco Research | 2021 | 22 |
| 19 | Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis | International Journal of Cancer | 2023 | 17 |
| 20 | Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma | World Journal of Clinical Oncology | 2018 | 14 |
| 21 | Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis | International Journal of Cancer | 2023 | 14 |
| 22 | Vape Shop Owners/Managers’ Opinions About FDA Regulation of E-Cigarettes | Nicotine and Tobacco Research | 2021 | 13 |
| 23 | Vape shop owners’/managers’ attitudes about CBD, THC, and marijuana legal markets | Preventive Medicine Reports | 2020 | 13 |
| 24 | Genomic features of rapid versus late relapse in triple negative breast cancer | BMC Cancer | 2021 | 10 |
| 25 | Care Disparities Across the Health Care Continuum for Older Adults: Lessons From Multidisciplinary Perspectives | American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting | 2021 | 9 |
| 26 | Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment | Annals of Emergency Medicine | 2019 | 8 |
| 27 | A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy | Annals of Oncology | 2016 | 5 |
| 28 | Value-Added Decisions in Oncology | American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting | 2019 | 5 |
| 29 | Aggressive Subsets of Metastatic Triple Negative Breast Cancer | Clinical Breast Cancer | 2020 | 5 |
| 30 | Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. | Journal of Clinical Oncology | 2019 | 5 |
| 31 | First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population | Future Oncology | 2022 | 5 |
| 32 | The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies | Journal of Gastrointestinal Surgery | 2021 | 4 |
| 33 | Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor. | Journal of Clinical Oncology | 2018 | 4 |
| 34 | Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy. | Journal of Clinical Oncology | 2019 | 4 |
| 35 | Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database. | Journal of Clinical Oncology | 2017 | 4 |
| 36 | Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC). | Journal of Clinical Oncology | 2021 | 3 |
| 37 | Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival | PLoS ONE | 2023 | 3 |
| 38 | Utilization of an audit tool to evaluate accuracy of treatment summary and survivorship care plans | Journal of Cancer Survivorship | 2019 | 2 |
| 39 | Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities. | Journal of Clinical Oncology | 2018 | 2 |
| 40 | Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study. | Journal of Clinical Oncology | 2019 | 2 |
| 41 | The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). | Journal of Clinical Oncology | 2019 | 2 |
| 42 | Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study | Breast Cancer Research | 2022 | 2 |
| 43 | Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. | Journal of Clinical Oncology | 2021 | 1 |
| 44 | OA06.04 Constructing a Global Molecular Database for Thoracic Malignancies: The IASLC Molecular Subcommittee Lung Cancer Dataset | Journal of Thoracic Oncology | 2021 | 1 |
| 45 | Abstract 933: The expression of PRMT5 methyltransferase mediates cell survival and metastatic phenotype in malignant melanoma | Journal of Thoracic Oncology | 2011 | 1 |
| 46 | Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort | JCO Oncology Practice | 0 | 1 |
| 47 | CA 19-9 as a Serum Biomarker in Cancer | JCO Oncology Practice | 2014 | 0 |
| 48 | Willard J Visek, MD, PhD (1922–2014), | Journal of Nutrition | 2015 | 0 |
| 49 | Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour | Annals of Oncology | 2019 | 0 |
| 50 | Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors | Mediastinum | 2019 | 0 |
